NeuroDerm begins Phase II trial of cognitive impairment treatment

The new product is based on pre-clinical research that showed that ND0801 prevented desensitization of nicotinic receptors.

Patch company NeuroDerm Ltd. today announced that it is beginning a Phase IIa clinical trial for a new product ND0801 to treat adults with attention and concentration problems (ADHD/ADD). The company develops skin patches to treat various illnesses by absorbing treatments via the central nervous system.

ND0801 is a patch that uniquely combines nicotinic activities for improving cognitive functions. The trial will examine the patch's effect on a range of illnesses that result in cognitive impairment such as Alzheimer's disease, schizophrenia, and Parkinson's disease in its advanced stages.

The new product is based on pre-clinical research that showed that ND0801 prevented desensitization of nicotinic receptors (which contributes to nicotine addiction) that occurs during repeated exposure to nicotine.

Research has indicated the involvement of the nicotinic system in the brain in a range of illnesses and disturbances of the nervous system and these are targeted by a number of treatments under development that are similar to nicotine. Nicotine itself has limited potential as a treatment because it desensitizes nicotinic receptors.

NeuroDerm believes that if the ND0801 trial succeeds in preventing desensitization, then it could be effective in treating cognitive problems and other illnesses linked to the central nervous system.

The ND0801 trial will take place at two Israeli hospitals with the participation of 45 patients. The trial will investigate safety, dosage, and the cognitive improvement in patients.

NeuroDerm chairman and CEO Oded Lieberman said, "Beginning this trial represents a significant milestone for us. It represents our entry into clinical development of a second unique and innovative product, this time for the treatment of attention and concentration problems.

NeuroDerm's first product NDO0611 is in clinical trials for the treatment of Parkinson's disease.

Published by Globes, Israel business news - www.globes-online.com - on November 9, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Gev Hadari credit: Nati Hortig Sompo Israel appoints Gev Hadari as cybersecurity head

Hadari's expertise spans penetration testing, including Red Team operations, web applications, mobile applications, OT/IOT products, and both external and internal assessments.

Attack drones credit: Shutterstock IDF issues tender for 5,000 Israeli-made attack drones

Critics of the tender say the number being procured is insufficient and thewre are security concerns about Chinese components.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018